
Non–Small Cell Lung Cancer



American Society of Clinical Oncology. ASCO Post. 2017. http://www.ascopost.com/issues/december-25-2017/lung-cancer-in-never-smokers-a-complex-clinical-phenomenon/



Source: Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. Lancet. 2016;387:1354-1356. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01125-3/fulltext

Approved Targeted Therapies as of 2018

EGFR Erlotinib, Gefitinib, Afatinib, Dacomitinib and Osimertinib

Source: Treating non-small cell lung cancer: targeted therapy drugs for non-small cell lung cancer. American Cancer Society. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/treating.html



ALK

Crizotinib, Ceritinib, Alectinib, Brigatinib and Lorlatinib

BRAF

Combination of Dabrafenib and Trametinib